Oct.12 — Johns Hopkins Bloomberg School of Public Health Vice Dean Joshua Sharfstein discusses President Donald Trump’s Covid-19 treatment claims and explains the flawed thinking behind herd immunity. He speaks on “Bloomberg Surveillance.” The Bloomberg School of Public Health is…
Oct.11 — President Donald Trump on Sunday pitched what he called his post-infection immunity to Covid-19 as an advantage over Democratic presidential nominee Joe Biden. Bloomberg’s Ros Krasny reports on “Bloomberg Daybreak: Australia.”
President Trump’s gender, age and weight are factors that make him more vulnerable to developing severe COVID-19, and give him a risk of around 4% of dying from it, according to health experts Subscribe: Reuters brings you the latest business,…
COVID-19 is reshaping almost every aspect of our society, including our health care systems. PhRMA and Bloomberg recently hosted a virtual event to discuss how this ongoing crisis continues to shape the evolution of the clinical and research ecosystem and…
Top U.S. infectious disease expert Anthony Fauci said he was “cautiously optimistic” that by the end of the year there would be at least one vaccine for the coronavirus. Subscribe: Reuters brings you the latest business, finance and breaking news…
#covid19 #hydroxychloroquine #henryford Henry Ford Hospital health system published a study showing that Hydroxychloroquine reduces mortality in COVID-19 patients when monitored for cardiac side effects and when the treatment is started within 24-48 hours after admission. Reference:
